EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis

Luc Calvin Owono Owono, Melalie Keita, Eugene Megnassan, Vladimir Frecer, Stanislav Miertus

Tuberculosis Research and Treatment · 2013 · 2013 · 1-13

DOI: 10.1155/2013/670836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tuberculosis Research and Treatment, 2013. Verfasst von Luc Calvin Owono Owono und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Simulations and Biomolecular Physics, Advanced Teachers Training College, University of Yaoundé I, P.O. Box 47, Yaoundé, Cameroon ; Ce…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We design here new nanomolar antituberculotics, inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase (TMPK mt ), by means of structure-based molecular design. 3D models of TMPK mt -inhibitor complexes have been prepared from the crystal structure of TMPK mt cocrystallized with the natural substrate deoxythymidine monophosphate (dTMP) (1GSI) for a training set of 15 thymidine analogues (TMDs) with known activity to prepare a QSAR model of interaction establishing a correlation between the free energy of complexation and the biological activity. Subsequent validation of the predictability of the model has been performed with a 3D QSAR pharmacophore generation. The structural information derived from the model served to design new subnanomolar thymidine analogues. From molecular modeling investigations, the agreement between free energy of complexation ( Δ Δ G com ) and K i values explains 94% of the TMPK mt inhibition ( p K i = - 0.2924 Δ Δ G com + 3.234 ; R 2 = 0.94 ) by variation of the computed Δ Δ G com and 92% for the pharmacophore (PH4) model ( p K i = 1.0206 × p K i pred - 0.0832 , R 2 = 0.92 ). The analysis of contributions from active site residues suggested substitution at the 5-position of pyrimidine ring and various groups at the 5′-position of the ribose. The best inhibitor reached a predicted K i of 0.155 nM. The computational approach through the combined use of molecular modeling and PH4 pharmacophore is helpful in targeted drug design, providing valuable information for the synthesis and prediction of activity of novel antituberculotic agents.

Autor:innen und Institutionen

  • Laboratory for Simulations and Biomolecular Physics, Advanced Teachers Training College, University of Yaoundé I, P.O. Box 47, Yaoundé, Cameroon ; Centre for Atomic Molecular Physics and Quantum Optics (CEPAMOQ), Univer…

Zitieren

APA

Owono Owono, L. C., Keita, M., Megnassan, E., Frecer, V., & Miertus, S. (2013). Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis. Tuberculosis Research and Treatment, 2013, 1-13. https://doi.org/10.1155/2013/670836

Vancouver

Owono Owono LC, Keita M, Megnassan E, Frecer V, Miertus S. Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis. Tuberculosis Research and Treatment. 2013;2013:1-13. doi:10.1155/2013/670836

BibTeX
@article{OwonoOwono2013,
  author = {Owono Owono, Luc Calvin and Keita, Melalie and Megnassan, Eugene and Frecer, Vladimir and Miertus, Stanislav},
  title = {Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis},
  journal = {Tuberculosis Research and Treatment},
  year = {2013},
  volume = {2013},
  pages = {1--13},
  doi = {10.1155/2013/670836}
}
Kostenlos starten →